Scientific Data
May 21, 2026
Leonardo Novelli, Devon Stoliker, Tamrin Barta et al.
PsiConnect is a large-scale neuroimaging study designed to investigate context-dependent neural and subjective effects of psilocybin using multimodal neuroimaging. It combines functional, structural, and diffusion-weighted MRI with EEG to examine brain activity in 62 participants before and after a 19 mg dose of psilocybin. The design includes resting-state scans and three naturalistic...
Psychedelic Medicine
March 1, 2026
Jennifer Pincombe, Martin L Williams, Sean Carruthers et al.
Background: Psilocybin-assisted psychotherapy (PAP) may be an effective intervention for a range of mental disorders. However, there appears to be a relative lack of qualitative evidence to complement emerging quantitative findings. To our knowledge, no reviews have systematically mapped the literature on qualitative studies on PAP for the treatment of mental disorders with the intent to...
General Hospital Psychiatry
2026
Martin L Williams, Karen Hitchcock, Angus H Miller et al.
Clinical research in psychedelic-assisted therapies is flourishing following the resumption of human trials exploring classic psychedelics and their therapeutic application to a range of mental health conditions. Translation from research to the clinic is underway in Australia and appears imminent in several other countries. Classic psychedelics function primarily as agonists of a subgroup of...
Front Psychiatry
April 23, 2025
Martin L Williams, Deborah Rudin, Yasmin Schmid et al.
However, psilocybin is but one of scores of compounds belonging to two main chemical classesphenethylamines and tryptamines -along with ergolines and an expanding array of other (mostly heterocyclic) alkaloids -that act as agonists of the serotonin 5-HT2A, 5-HT2C and 5-HT1A receptors responsible for the various phenomenological and putative therapeutic effects of classic psychedelics (8). In...
Focus (American Psychiatric Publishing)
July 1, 2024
Claire J. Foldi, Paul Liknaitzky, Martin L Williams et al.
Anorexia nervosa (AN) has the highest mortality rate of any psychiatric disease, yet available pharmacological treatments are largely ineffective due, in part, to an inadequate understanding of the neurobiological drivers that underpin the condition. The recent resurgence of research into the clinical applications of psychedelic medicine for a range of mental disorders has highlighted the...
Australian and New Zealand journal of psychiatry
September 28, 2016
N. Strauss, Stephen Bright, Martin L Williams
10 citations
Australian & New Zealand Journal of Psychiatry, 50(11) A recent review in Pharmacological Reviews highlights that over the last decade, a renaissance has occurred in psychedelic drug research in North America and Europe as investigators at Johns Hopkins School of Medicine, University of California, Los Angeles (UCLA), New York University and Imperial College London have embarked on studies that...
Journal of psychopharmacology (Oxford, England)
August 1, 2014
Will Lawn, Monica J Barratt, Martin L Williams et al.
The NBOMe compounds are a novel series of hallucinogenic drugs that are potent agonists of the 5-HT2A receptor, have a short history of human consumption and are available to buy online, in most countries. In this study, we sought to investigate the patterns of use, characteristics of users and self-reported effects. A cross-sectional anonymous online survey exploring the patterns of drug use...
Crop Science
March 1, 1971
Martin L Williams, R. F. Barnes, John M. Cassady
20 citations
We determined the types and amounts of alkaloids found in four reed canarygrass ( Phalaris arundinacea L.) genotypes that differed in palatability. The palatability differences had been demonstrated previously in cafeteria grazing trials with lambs. The following alkaloids were identified in reed canarygrass by combinations of gas‐liquid chromatography, thin‐layer chromatography, and mass...